 |
About UsTargeting Systems is a San Diego-based biotechnology company developing proprietary technologies for non-viral gene delivery, endogenous biologic expression, ultrasensitive bioluminescent imaging, accelerated CHO cell-line development, and drug discovery. Targeting Systems was founded in 1996 entirely with support from an NIH SBIR Phase I grant focused on targeted gene delivery. The company maintains a portfolio of life science research reagents, including transfection reagents, improved luciferase reporters, multiplexed luciferase assays for HTS, and LentiGlo™ prepackaged lentiviral reporters for in vivo imaging. Select products have been commercialized through OEM/private-label arrangements with established life science companies. Product information is available at: https://targetingsystems.net/products.php Targeting Systems' technologies are supported by an experienced scientific/advisory team with expertise spanning gene delivery, biologics development, immunology, molecular imaging, and cell-line development. The company also maintains long-standing relationships with specialized CROs and contract manufacturing partners supporting in vivo studies, translational research, and GMP formulation activities. The company's technology portfolio is protected by multiple issued and pending patents spanning gene delivery, biologics development, molecular imaging, reporter systems, and drug discovery technologies. Leadership
Rampyari Walia, Ph.D.
Founder and Chief Executive Officer
Dr. Rampyari Walia is the Founder and Chief Executive Officer of Targeting Systems. She has more than 30 years of experience in biotechnology spanning academia, drug discovery, gene delivery, molecular imaging, biologics development, and translational research. Dr. Walia received her Ph.D. in Biochemistry from the University of Texas and subsequently held faculty appointments at both the University of Alabama at Birmingham and Vanderbilt University. She founded Targeting Systems in 1996 following receipt of an NIH SBIR Phase I award focused on targeted gene delivery. Dr. Walia has led the development of multiple proprietary technology platforms, including non-viral gene delivery systems for endogenous biologic expression, NIRGlo™ bioluminescent imaging technologies, CloneBeacon™ and HiXP™ accelerated cell-line development platforms, and a portfolio of bioluminescent assay technologies for drug discovery. These technologies are covered by several issued and pending patents. Link to Dr Walia's CV: View CV Technical Team
Kolari S. Bhat, Ph.D.
Molecular Biology and Vector Engineering
Dr. Bhat has worked with Targeting Systems since 2005 and provides expertise in construct design, plasmid engineering, mutagenesis, DNA sequencing, molecular assay development, and gene-expression technologies. Dr. Bhat received his Ph.D. in Biochemistry from the Indian Institute of Science and completed postdoctoral training at the University of Pennsylvania. He previously served as Director of the DNA Core Laboratory at Vanderbilt University and as a Senior Scientific Fellow at the National Institute of Allergy and Infectious Diseases (NIAID/NIH). He is currently also the Chief Executive Officer of Gene PASS Inc. and has extensive experience in construct design, vector engineering, DNA quality control, and molecular assay development. Dr. Bhat has contributed to the design and development of numerous Targeting Systems gene delivery and reporter constructs. 
Aleksey Yevtodiyenko, Ph.D.
In Vivo Imaging and Bioluminescence Specialist
Dr. Aleksey Yevtodiyenko is a molecular biologist and imaging specialist with more than twenty years of experience in cancer biology, molecular imaging, and bioluminescence technologies. He previously served as Senior Scientist at PerkinElmer, where he developed reagents and applications for optical preclinical imaging systems including bioluminescence, fluorescence, CT, and multimodal imaging platforms. Dr. Yevtodiyenko is currently Founder and CEO of Glow Biosciences. He has supported execution of multiple in vivo imaging studies for the LentiGlo™ and NIRGlo™ product lines. Scientific Advisors
Edward A. Sausville, M.D., Ph.D.
Oncology and Translational Medicine Advisor
Dr. Edward Sausville is a nationally recognized medical oncologist, cancer drug developer, and former Associate Director of the Developmental Therapeutics Program at the National Cancer Institute (NCI). During his tenure at NCI, he directed preclinical cancer drug discovery and development programs involving hundreds of scientists nationwide and helped advance numerous agents into clinical development, including Velcade®, Romidepsin, and Halaven®. He subsequently served as Associate Director for Clinical Research and Deputy Director of the University of Maryland Greenebaum Comprehensive Cancer Center. Dr. Sausville provides strategic guidance for Targeting Systems' oncology and immunotherapy programs, including development of endogenous immune engager technologies and translational development strategies. 
Nigel Killeen, D.Phil.
Immunology Advisor
Dr. Nigel Killeen is an internationally recognized immunologist, entrepreneur, and biotechnology executive with expertise spanning academic immunology, antibody discovery, cellular engineering, and cytokine engineering. He previously served as Associate Professor of Microbiology and Immunology at the University of California, San Francisco and later as Chief Scientific Officer of Trianni Inc., where he helped develop the human antibody discovery platform that became the Trianni Mouse®. Dr. Killeen is currently Co-Founder and Chief Scientific Officer of Neptune Biosciences and has co-founded several biotechnology companies focused on antibody engineering and immunotherapy. He provides scientific guidance for Targeting Systems' immune engager, antibody expression, and immunotherapy programs. Research & Development Resources / CROs Lumigenics LLC (Hercules, California) – In vivo imaging, animal studies and preclinical research services  Bioexpression and Fermentation Facility, University of Georgia Our Core Technologies
Partnerships and LicensingTargeting Systems is actively seeking strategic partnerships and licensing opportunities. Interested in reaching out to know more about our technology or products? Please email us: info@targetingsystems.net Licensing Contact: rampyariwalia@targetingsystems.net InnovationsBioluminescence :The Best and the Brightest Single, dual, triple and quintuple reporter systems spanning the spectrum, tailored for high throughput screening.
High Throughput Screening :We are the first to have developed single solution-based triple luciferase reporter assays - 3 different secreted luciferases activities in the same sample can be measured with one assay solution by spectral resolution using appropriate filters in the luminometer. Saves screening time, increased assay sensitivity(brighter signal) and compatibility with HTS. Cells remain viable for downstream applications. Lenti-Luciferase Product lines LentiPower™ and LentiGlo™Several issued and pending patents cover our portfolio of unique luciferases and assay reagents. Gene Delivery - Targefect™ / Virofect™ Transfection Reagents :
Protein Delivery :Unique protein delivery reagents that have proved useful for diverse applications such as differentiation of human stem cells into specific lineages and delivery of a variety of functionally active proteins into macrophages and primary cells. See our ppt presentation for an overview of performance and endorsements link Protein Expression :Stem Cells :
Patents on stem cell tracking, differentiation and de-differentiation Legal Gaussia Luciferase Limited Use License Gaussia Expression Vector users: Label License 1-28-08 | Label License with signature 1-28-08 |